Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 11 min ago
Peer-reviewedCC BYBMC pulmonary medicine

Membranous obliterans bronchitis after hematopoietic stem cell transplantation: case report.

  1. 1Guangxi Medical University, Nanning, Guangxi Zhuangzu Autonomous Region, 530021, P. R. China.
  2. 2The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, 530021, P.R. China.
  3. 3The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, 530021, P.R. China. [email protected].

Abstract

Background

Pulmonary complications following hematopoietic stem cell transplantation (HSCT) are crucial factors affecting the prognosis of pediatric patients. Among them, membranous obliterative bronchitis (MOB) is rare, lacks sufficient clinical recognition, and is easily confused with bronchiolitis obliterans (BO), often leading to delayed diagnosis and extremely poor treatment outcomes. This study aimed to clarify the clinical characteristics, diagnostic key points of MOB after HSCT and its association with graft-versus-host disease (GVHD), so as to bridge the current knowledge gap regarding this rare fatal complication in clinical practice.Methods

A retrospective analysis was conducted, enrolling 2 pediatric patients with severe β-thalassemia who were diagnosed with MOB after HSCT. Data including clinical manifestations, chest computed tomography (CT), pulmonary function, fiberoptic bronchoscopy, pathological biopsy, metagenomic next-generation sequencing (mNGS) of bronchoalveolar lavage fluid, and immune indicators were systematically collected. The diagnosis and treatment processes were summarized, and the pathogenesis was analyzed. The 2 patients developed progressive dyspnea at 7 months and 4 months after HSCT, respectively, both presenting with severe obstructive ventilatory dysfunction in pulmonary function tests (FEV1% predicted: 23.2% and 22.1%, respectively). Fiberoptic bronchoscopy revealed characteristic membranous stenosis or occlusion in segmental/subsegmental bronchi (3rd-4th generation), and bronchiectasis was observed on chest CT in both cases. Both patients were complicated with active GVHD and opportunistic infections. The conditions could not be reversed despite immunosuppressive therapy, anti-infective treatment, and interventional fiberoptic bronchoscopy, and both eventually died of respiratory failure. Immune monitoring indicated excessive activation of CD8 + T cells, persistently lowered CD4/CD8 ratio, and decreased B cell counts.Conclusions

MOB after HSCT is a rare fatal complication that may be closely related to GVHD progression, immune dysregulation, and infectious triggers. Membranous occlusion under fiberoptic bronchoscopy is the key to definitive diagnosis, and existing therapeutic measures have limited efficacy. Clinically, early fiberoptic bronchoscopy should be performed for dyspneic patients complicated with GVHD after HSCT, and the prevention and control of GVHD as well as infection prophylaxis should be strengthened. Targeted immune intervention strategies should be explored in the future to improve prognosis.

Related

  1. Exercise capacity and handgrip strength following dumbbell-assisted diaphragmatic breathing training in patients with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation: a prospective single-arm study
    Xinyu Yuan, Wei Ge, Xiaojie Zhu +3
    Frontiers in MedicinePeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  2. Case Report: SAPHO syndrome mimicking osseous relapse after haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia
    Wenhui Zhang, Xiaolin Ma, Xianglan Liu +6
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Secondary Pulmonary Alveolar Proteinosis after Allogeneic Hematopoietic Stem Cell Transplantation in the Setting of an Respiratory Syncytial Virus Infection: A Case Report
    Yuki Mori, Koichi Nakase, Risa Hashida +2
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  4. Pirfenidone in bronchiolitis obliterans syndrome after lung transplantation: two negative trials, one clearer path forward.
    Narat Srivali
    Journal of thoracic diseasePeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMC
  5. Rare primary bilateral ovarian myeloid sarcoma preceding acute myeloid leukemia: ovarian-sparing management with long-term ovarian function and pregnancy after allogeneic hematopoietic stem cell transplantation-a case report.
    Aruna Tantia, Shashi Khanna, Poonam Kapoor +1
    AJOG global reportsPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
BibTeX
@article{pan2026membranous,
  title = {{Membranous obliterans bronchitis after hematopoietic stem cell transplantation: case report.}},
  author = {Weiquan Pan and Yang Li and Changjin Wei and Zhiyi He and Jianming Luo and Guopeng Liao and Lingyun Chen and Meihua Li},
  journal = {BMC pulmonary medicine},
  year = {2026},
  month = aug,
  doi = {10.1186/s12890-026-04539-x},
  url = {https://europepmc.org/article/MED/42958146},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Membranous obliterans bronchitis after hematopoietic stem cell transplantation: case report.
AU  - Weiquan Pan
AU  - Yang Li
AU  - Changjin Wei
AU  - Zhiyi He
AU  - Jianming Luo
AU  - Guopeng Liao
AU  - Lingyun Chen
AU  - Meihua Li
PY  - 2026
DA  - 2026/08/01
JO  - BMC pulmonary medicine
DO  - 10.1186/s12890-026-04539-x
UR  - https://europepmc.org/article/MED/42958146
AB  - Background  Pulmonary complications following hematopoietic stem cell transplantation (HSCT) are crucial factors affecting the prognosis of pediatric patients. Among them, membranous obliterative bronchitis (MOB) is rare, lacks sufficient clinical recognition, and is easily confused with bronchiolitis obliterans (BO), often leading to delayed diagnosis and extremely poor treatment outcomes. This study aimed to clarify the clinical characteristics, diagnostic key points of MOB after HSCT and its association with graft-versus-host disease (GVHD), so as to bridge the current knowledge gap regarding this rare fatal complication in clinical practice.Methods  A retrospective analysis was conducted, enrolling 2 pediatric patients with severe β-thalassemia who were diagnosed with MOB after HSCT. Data including clinical manifestations, chest computed tomography (CT), pulmonary function, fiberoptic bronchoscopy, pathological biopsy, metagenomic next-generation sequencing (mNGS) of bronchoalveolar lavage fluid, and immune indicators were systematically collected. The diagnosis and treatment processes were summarized, and the pathogenesis was analyzed. The 2 patients developed progressive dyspnea at 7 months and 4 months after HSCT, respectively, both presenting with severe obstructive ventilatory dysfunction in pulmonary function tests (FEV1% predicted: 23.2% and 22.1%, respectively). Fiberoptic bronchoscopy revealed characteristic membranous stenosis or occlusion in segmental/subsegmental bronchi (3rd-4th generation), and bronchiectasis was observed on chest CT in both cases. Both patients were complicated with active GVHD and opportunistic infections. The conditions could not be reversed despite immunosuppressive therapy, anti-infective treatment, and interventional fiberoptic bronchoscopy, and both eventually died of respiratory failure. Immune monitoring indicated excessive activation of CD8 + T cells, persistently lowered CD4/CD8 ratio, and decreased B cell counts.Conclusions  MOB after HSCT is a rare fatal complication that may be closely related to GVHD progression, immune dysregulation, and infectious triggers. Membranous occlusion under fiberoptic bronchoscopy is the key to definitive diagnosis, and existing therapeutic measures have limited efficacy. Clinically, early fiberoptic bronchoscopy should be performed for dyspneic patients complicated with GVHD after HSCT, and the prevention and control of GVHD as well as infection prophylaxis should be strengthened. Targeted immune intervention strategies should be explored in the future to improve prognosis.
SN  - 1471-2466
ER  -